EA201992319A1 - Анти-cd33 антитела и способы их применения - Google Patents

Анти-cd33 антитела и способы их применения

Info

Publication number
EA201992319A1
EA201992319A1 EA201992319A EA201992319A EA201992319A1 EA 201992319 A1 EA201992319 A1 EA 201992319A1 EA 201992319 A EA201992319 A EA 201992319A EA 201992319 A EA201992319 A EA 201992319A EA 201992319 A1 EA201992319 A1 EA 201992319A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
ways
compositions
application
epitopes
Prior art date
Application number
EA201992319A
Other languages
English (en)
Inventor
Патрисия Калп
Хелен Лам
Арнон Розенталь
Сеунг Дзоо Ли
Нельс П. Нильсон
Роберт Пейхал
Original Assignee
ЭЛЕКТОР ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭЛЕКТОР ЭлЭлСи filed Critical ЭЛЕКТОР ЭлЭлСи
Priority claimed from PCT/US2018/045056 external-priority patent/WO2019028283A1/en
Publication of EA201992319A1 publication Critical patent/EA201992319A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение в целом относится к композициям, которые содержат антитела, например моноклональные, химерные, гуманизированные антитела, фрагменты антител и т.д., которые специфически связывают один или более эпитопов в белке CD33, например человеческом CD33 или CD33 млекопитающих, и имеют улучшенные и/или усиленные функциональные характеристики, и к применению таких композиций в профилактике, снижении риска или лечении пациента.
EA201992319A 2018-05-04 2018-08-02 Анти-cd33 антитела и способы их применения EA201992319A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862667388P 2018-05-04 2018-05-04
PCT/US2018/045056 WO2019028283A1 (en) 2017-08-03 2018-08-02 ANTI-CD33 ANTIBODIES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
EA201992319A1 true EA201992319A1 (ru) 2020-03-25

Family

ID=69942823

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992319A EA201992319A1 (ru) 2018-05-04 2018-08-02 Анти-cd33 антитела и способы их применения

Country Status (1)

Country Link
EA (1) EA201992319A1 (ru)

Similar Documents

Publication Publication Date Title
PH12019502463A1 (en) Anti-cd33 antibodies and methods of use thereof
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
EA201790342A1 (ru) Антитела к trem2 и способы их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
EA201791127A1 (ru) Антитела, содержащие модифицированные константные участки тяжелой цепи
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
EA202092460A1 (ru) Антитела к ox40 и способы применения
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA202190235A1 (ru) Антитела к cd33 и способы их применения
EA202091747A1 (ru) Составы антитела b7-h4
EA202092420A1 (ru) Антитело против pd-l1 и его применение
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
EA202090791A1 (ru) Агонистические антитела против cd40
MX2019011520A (es) Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos.
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
MX2022007156A (es) Metodos de uso de anticuerpos anti-cd33.
EA201992319A1 (ru) Анти-cd33 антитела и способы их применения